See what the experts are saying about treatment with NINLARO® (ixazomib)
NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
The importance of long-term* proteasome inhibition in multiple myeloma
Oral proteasome inhibition in the evolving multiple myeloma treatment landscape
- *Defined as treatment to progression or unacceptable toxicity.
- Dr. Niesvizky and Dr. Vescio are paid consultants of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
- This content is intended for informational purposes only and is not a substitute for your clinical knowledge or professional judgment.